Is your young adult child a saver or a spender? Whether your child is moving onto higher education or going into the workforce after their time at New York City Public Schools (NYCPS), how they manage ...

Michael Harrison was leading Louisville’s Independent Monitor Team, but Mayor Craig Greenberg announced Tuesday he’s leaving ELEFA for other opportunities. The Director of Metro EMA says as of Tuesday ...

It’s official: Twitter.com is about to bite the dust forever. According to a series of tweets from X’s @Safety account, posted between October 24 and October 25, the social media platform plans to ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

In today's hyper-connected world, cyber threats are more sophisticated and frequent than ever - ransomware attacks, data breaches, social engineering scams, and advanced persistent threats targeting ...

– Enrollment remains ongoing in a Phase 2 proof-of-concept study of ALTO-101 in patients with CIAS – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--$ANRO #FastTrack ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...

AP-101, AL-S Pharma’s amyotrophic lateral sclerosis (ALS) therapy, was safe and well tolerated and led to clinically meaningful benefits for breathing and survival after one year of treatment. “We are ...

Phase 2 of AP-101 in sporadic ALS and mutant SOD1-ALS met its primary safety and tolerability endpoint Clinically meaningful changes in outcome measures and stabilization of biomarkers were observed ...

VOY-101 gene therapy for GA showed safety and tolerability in phase 1, with no significant adverse effects observed. The therapy uses a single intravitreal injection to deliver CFH gene protection, ...